Insmed, Inc. $INSM Stock Position Lifted by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC raised its stake in Insmed, Inc. (NASDAQ:INSM) by 6.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 480,000 shares of the biopharmaceutical company’s stock after buying an additional 30,000 shares during the quarter. Insmed accounts for about 4.1% of Affinity Asset Advisors LLC’s holdings, making the stock its 4th biggest position. Affinity Asset Advisors LLC’s holdings in Insmed were worth $78,490,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. iA Global Asset Management Inc. lifted its holdings in shares of Insmed by 15,973.5% during the 4th quarter. iA Global Asset Management Inc. now owns 26,682 shares of the biopharmaceutical company’s stock valued at $4,644,000 after buying an additional 26,516 shares during the last quarter. Monashee Investment Management LLC bought a new stake in shares of Insmed in the 4th quarter valued at approximately $8,702,000. Nordea Investment Management AB acquired a new position in Insmed in the fourth quarter worth approximately $3,492,000. Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Insmed by 89.5% in the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 103,308 shares of the biopharmaceutical company’s stock worth $17,981,000 after buying an additional 48,779 shares during the last quarter. Finally, Danske Bank A S raised its position in Insmed by 4,494.1% during the fourth quarter. Danske Bank A S now owns 110,258 shares of the biopharmaceutical company’s stock valued at $19,189,000 after acquiring an additional 107,858 shares in the last quarter.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 10,699 shares of the company’s stock in a transaction on Thursday, July 9th. The stock was sold at an average price of $117.40, for a total value of $1,256,062.60. Following the completion of the transaction, the chief executive officer directly owned 259,058 shares in the company, valued at approximately $30,413,409.20. This represents a 3.97% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Roger Adsett sold 2,370 shares of the business’s stock in a transaction on Wednesday, June 3rd. The shares were sold at an average price of $102.27, for a total transaction of $242,379.90. Following the completion of the sale, the chief operating officer directly owned 98,603 shares in the company, valued at $10,084,128.81. This trade represents a 2.35% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 54,590 shares of company stock worth $5,793,738 over the last quarter. 2.10% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on the stock. Truist Financial reduced their target price on shares of Insmed from $205.00 to $185.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Insmed in a report on Friday, July 17th. JPMorgan Chase & Co. reduced their price objective on shares of Insmed from $180.00 to $179.00 and set an “overweight” rating for the company in a research note on Monday, June 8th. Barclays upped their price objective on shares of Insmed from $231.00 to $237.00 and gave the stock an “overweight” rating in a report on Wednesday, April 1st. Finally, Wells Fargo & Company raised their target price on Insmed from $160.00 to $161.00 and gave the company an “overweight” rating in a report on Wednesday, July 15th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $209.13.

Insmed Price Performance

NASDAQ:INSM opened at $106.92 on Friday. The company has a debt-to-equity ratio of 0.80, a current ratio of 4.47 and a quick ratio of 4.10. Insmed, Inc. has a one year low of $90.39 and a one year high of $212.75. The company has a fifty day moving average price of $105.20 and a 200 day moving average price of $133.54. The stock has a market cap of $23.17 billion, a P/E ratio of -18.59 and a beta of 0.78.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.76) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.90) by $0.14. The company had revenue of $305.96 million for the quarter, compared to the consensus estimate of $300.81 million. Insmed had a negative net margin of 144.44% and a negative return on equity of 130.11%. The business’s revenue was up 229.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.42) EPS. Analysts anticipate that Insmed, Inc. will post -2.43 earnings per share for the current year.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.